Drug intelligence / Profile preview

carboplatin + paclitaxel + Reolysin

Development stage: Preclinical
Lead developer: Oncolytics Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules
Administration: Intravenous

Overview

A combination therapy consisting of two chemotherapy agents (carboplatin and paclitaxel) plus an oncolytic virus (Reolysin/pelareorep). Carboplatin is a platinum-based chemotherapy that works by crosslinking DNA, interfering with cell division. Paclitaxel is a taxane that stabilizes microtubules, preventing cell division. Reolysin is a formulation of wild-type reovirus that selectively replicates in and kills cancer cells with activated Ras pathways. The combination leverages multiple mechanisms to target cancer cells, including DNA damage, mitotic arrest, and virus-mediated cell death. Reolysin also demonstrates anti-angiogenic properties through induction of CXCL10.

Brand names: REOLYSIN
Other names: carboplatin + paclitaxel + pelareorepCarbo-Taxol + Reolysin

Targets

MicrotubuleSialoglycan (Cell-surface sialoglycan)DNAJAM-A (Junctional adhesion molecule A)

Beyond the preview

Go deeper on carboplatin + paclitaxel + Reolysin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + paclitaxel + Reolysin.

Explore the full profile